98%
921
2 minutes
20
To develop effective anti-lung cancer vaccines, we directly mixed mycobacterial heat shock protein 65 (MHSP65) and tumor cell lysate (TCL) from Lewis lung cancer cells in vitro and tested its efficacy on stimulating anti-tumor immunity. Our results showed that MHSP65-TCL immunization significantly inhibited the growth of lung cancer in mice and prolonged the survival of lung cancer bearing mice. In vivo and in vitro data suggest that MHSP65-TCL could induce specific CTL responses and non-specific immunity, both of which could contribute to the tumor inhibition. Thus, this report provides an easy approach to prepare an efficient TCL based tumor vaccine.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030583 | PMC |
http://dx.doi.org/10.1007/s00262-010-0816-2 | DOI Listing |
Ann Surg Oncol
September 2025
Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Background: RUNX3 acts as a tumor suppressor gene in non-small-cell lung cancer (NSCLC), yet its specific biological mechanism is still unclear. This study aimed to uncover tumor microenvironment (TME) changes in NSCLC with varying RUNX3 expression statuses through single-cell RNA sequencing.
Patients And Methods: In total, seven patients with NSCLC with detailed pathological data were involved, with three both paracancerous and cancerous tissue samples.
J Cardiothorac Vasc Anesth
August 2025
Department of Anesthesiology and Critical Care, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Objectives: To quantify intraoperative pulmonary arterial catheter (PAC) use during cardiac surgery and identify hospital-, anesthesiologist-, and patient-level factors associated with PAC utilization.
Design: A cross-sectional, observational study using generalized logistic mixed models to examine variations in PAC use.
Setting: Fifty-three US academic hospitals participating in the Multicenter Perioperative Outcomes Group (MPOG) national registry PARTICIPANTS: 145,343 adult patients undergoing cardiac surgery between January 1, 2016, and December 31, 2022.
Crit Rev Oncol Hematol
September 2025
Unit of Cancer Genetics, Institute of Genetic & Biomedical Research (IRGB), National Research Council (CNR), Traversa La Crucca n. 3, 07100, Sassari, Italy; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari, Viale San Pietro 43, 07100, Sassari, Italy. Electronic address: gpalmier
Mutations in the KRAS gene are prominent oncogenic drivers in non-small cell lung cancer (NSCLC), with multiple pathophysiological, clinical and prognostic implications. Although historically considered an "undruggable" target, recent research led to the development of specific KRAS-G12C inhibitors, like sotorasib and adagrasib which are currently approved for clinical use in patients affected by advanced NSCLC. However, the clinical utility of these drugs is often limited by resistance development through several biological mechanisms, including additional KRAS mutations, activation of compensatory pathways and metabolic reprogramming.
View Article and Find Full Text PDFClin Nutr ESPEN
September 2025
Duke University, Department of Surgery, Division of Trauma, Acute, and Critical Care Surgery, Durham, NC, USA. Electronic address:
Background: Up to 70% of lung cancer may be malnourished. This study aims to examine the effects of malnutrition on outcomes in lung cancer patients undergoing resection using modified GLIM criteria.
Methods: The study utilized the mGLIM criteria to identify malnourished patients.
Asian Nurs Res (Korean Soc Nurs Sci)
September 2025
The Fourth Affiliated Hospital of Hebei Medical University; Address: The Fourth Affiliated Hospital of Hebei Medical University, No. 12 Jiankang Road, Chang'an District, Shijiazhuang City, Hebei Province, 050000, People's Republic of China. Electronic address:
Purpose: To examine the effectiveness of virtual reality (VR)-guided imagery relaxation (VRGI) intervention in reducing anxiety among lung cancer surgery patients.
Methods: A randomized clinical trial was conducted at the Fourth Affiliated Hospital of Hebei Medical University (Shijiazhuang, Hebei, China) to recruit patients scheduled for their first elective endoscopic lung cancer surgery under general anesthesia between December 2023 and March 2024. Patients were randomly assigned in a 1:1 ratio to either the control group, receiving routine treatment and staged care in thoracic surgery, or the experimental group, receiving VRGI intervention in addition to the control group's protocol.